entertainment -WSS

entertainment

author：hotspot 2025-09-30 15:23:04 - browse：7

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： What should King Charles tell the public about his cancer?

leisure time

WSS

FDA panel gives mixed vote on blood pressure devices

Readout LOUD podcast: How biotech is using artificial intelligence

AstraZeneca challenges Medicare drug negotiation program

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Apellis safety probe of eye disease drug centers on injection needle

Medicare Advantage proposed rates disappoint insurers

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Medicare Advantage proposed rates disappoint insurers

Continuity nursing helped my family in our darkest PICU moments

Gilead might be held responsible for not developing a drug

Walensky prepares to leave CDC — and Congress — behind

FDA panel gives mixed vote on blood pressure devices

Medical leaders decry Supreme Court decision on affirmative action

What we’ve learned from the Aduhelm mess

How to save PrEP access — and even expand it

Private equity deals in Medicare Advantage declines

entertainment

Private equity deals in Medicare Advantage declines

How Long Island became the ‘eugenics capital of the world’

Vaccine advisory panel ACIP left half staffed by HHS

Radiation, mainstay of cancer treatment, begins a fade

AstraZeneca challenges Medicare drug negotiation program

What we’ve learned from the Aduhelm mess

hotspot

leisure time

hotspot

hotspot